Targeting glutamine metabolism in hepatic stellate cells alleviates liver fibrosis

Cell Death Dis. 2022 Nov 14;13(11):955. doi: 10.1038/s41419-022-05409-0.

Abstract

Glutamine metabolism plays an essential role in cell growth, and glutamate dehydrogenase (GDH) is a key enzyme. GDH promotes the metabolism of glutamate and glutamine to generate ATP, which is profoundly increased in multiple human cancers. Through in vitro and in vivo experiments, we verified that the small-molecule GDH inhibitor EGCG slowed the progression of fibrosis by inhibiting GDH enzyme activity and glutamine metabolism. SIRT4 is a mitochondrial enzyme with NAD that promotes ADP ribosylation and downregulates GDH activity. The role of SIRT4 in liver fibrosis and the related mechanisms are unknown. In this study, we measured the expression of SIRT4 and found that it was downregulated in liver fibrosis. Modest overexpression of SIRT4 protected the liver from fibrosis by inhibiting the transformation of glutamate to 2-ketoglutaric acid (α-KG) in the tricarboxylic acid cycle (TCA), thereby reducing the proliferative activity of hepatic stellate cells (HSCs). Collectively, our study reveals that SIRT4 controls GDH enzyme activity and expression, targeting glutamine metabolism in HSCs and alleviating liver fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Glutamate Dehydrogenase / metabolism
  • Glutamic Acid / metabolism
  • Glutamine* / metabolism
  • Hepatic Stellate Cells* / metabolism
  • Humans
  • Liver Cirrhosis / genetics

Substances

  • Glutamine
  • Glutamate Dehydrogenase
  • Glutamic Acid